Mutated KRAS plays an important role in many cancers. Although targeting KRAS directly is difficult, indirect inactivation via synthetic lethal partners (SLPs) is promising. Yet to date, there are no SLPs from high-throughput RNAi screening, which are supported by multiple screens. Here, we address this problem by aggregating and ranking data over three independent high-throughput screens. We integrate rankings by minimizing the displacement and by considering established methods such as RIGER and RSA.Our meta analysis reveals COPB2 as a potential SLP of KRAS with good support from all three screens. COPB2 is a coatomer subunit and its knock down has already been linked to disabled autophagy and reduced tumor growth. We confirm COPB2 as SLP in knock down experiments on pancreas and colorectal cancer cell lines.Overall, consistent integration of high throughput data can generate candidate synthetic lethal partners, which individual screens do not uncover. Concretely, we reveal and confirm that COPB2 is a synthetic lethal partner of KRAS and hence a promising cancer target. Ligands inhibiting COPB2 may, therefore, be promising new cancer drugs.
|Number of pages||15|
|Publication status||Published - 23 May 2017|
Sustainable Development Goals
- Cell Line, Tumor, Coatomer Protein/genetics, Colorectal Neoplasms/genetics, Gene Expression Regulation, Neoplastic, Gene Knockdown Techniques, Genomics/methods, High-Throughput Screening Assays, Humans, Neoplasms/genetics, Pancreatic Neoplasms/genetics, Proto-Oncogene Proteins p21(ras)/genetics, RNA Interference